Psychedelic-assisted therapies

The past, and the need to move forward responsibly

Research output: Contribution to journalComment / DebateOtherpeer-review

Abstract

Recent clinical studies illustrate that psychedelics such as LSD and psilocybin may represent much-needed new treatment options for mood disorders and alcohol and other drug use disorders. More clinical studies are required to confirm the safety and efficacy of psychedelic-assisted therapies, but the cultural stigma that has surrounded psychedelics since the 1960s has hindered research. This problem is amplified in Australia. There has been a complete absence of research into psychedelic therapies, and Australian-based research advocates claim to have encountered a number of barriers. In this commentary, we provide a brief account of the historical stigma associated with psychedelics, and an overview of the contemporary context of research into psychedelic-assisted therapies, including the purported barriers to research in Australia. In light of the complex history of psychedelics, we identify a number of pressing questions relating to the social and legal context that need to be addressed so that clinical studies can proceed. Research is needed to address such questions so that the nature and extent of purported barriers to clinical studies with psychedelics can be properly elucidated, and strategies developed – with practitioners, patients, families and other stakeholders – to responsibly address these barriers. This is important because it will enable Australian researchers to contribute robust evidence about the possible efficacy and safety of psychedelic therapies, and to facilitate local expertise needed to implement psychedelic-assisted therapies, should they prove efficacious.

Original languageEnglish
Pages (from-to)94-98
Number of pages5
JournalInternational Journal of Drug Policy
Volume70
DOIs
Publication statusPublished - 1 Aug 2019

Keywords

  • Addiction
  • LSD
  • Mood disorders
  • Psilocybin
  • Socio-political
  • Stigma

Cite this

@article{fc14432161074f1bbf8c4db9c26819de,
title = "Psychedelic-assisted therapies: The past, and the need to move forward responsibly",
abstract = "Recent clinical studies illustrate that psychedelics such as LSD and psilocybin may represent much-needed new treatment options for mood disorders and alcohol and other drug use disorders. More clinical studies are required to confirm the safety and efficacy of psychedelic-assisted therapies, but the cultural stigma that has surrounded psychedelics since the 1960s has hindered research. This problem is amplified in Australia. There has been a complete absence of research into psychedelic therapies, and Australian-based research advocates claim to have encountered a number of barriers. In this commentary, we provide a brief account of the historical stigma associated with psychedelics, and an overview of the contemporary context of research into psychedelic-assisted therapies, including the purported barriers to research in Australia. In light of the complex history of psychedelics, we identify a number of pressing questions relating to the social and legal context that need to be addressed so that clinical studies can proceed. Research is needed to address such questions so that the nature and extent of purported barriers to clinical studies with psychedelics can be properly elucidated, and strategies developed – with practitioners, patients, families and other stakeholders – to responsibly address these barriers. This is important because it will enable Australian researchers to contribute robust evidence about the possible efficacy and safety of psychedelic therapies, and to facilitate local expertise needed to implement psychedelic-assisted therapies, should they prove efficacious.",
keywords = "Addiction, LSD, Mood disorders, Psilocybin, Socio-political, Stigma",
author = "John Gardner and Adrian Carter and Kerry O'Brien and Kate Seear",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.drugpo.2019.05.019",
language = "English",
volume = "70",
pages = "94--98",
journal = "International Journal of Drug Policy",
issn = "0955-3959",
publisher = "Elsevier",

}

Psychedelic-assisted therapies : The past, and the need to move forward responsibly. / Gardner, John; Carter, Adrian; O'Brien, Kerry; Seear, Kate.

In: International Journal of Drug Policy, Vol. 70, 01.08.2019, p. 94-98.

Research output: Contribution to journalComment / DebateOtherpeer-review

TY - JOUR

T1 - Psychedelic-assisted therapies

T2 - The past, and the need to move forward responsibly

AU - Gardner, John

AU - Carter, Adrian

AU - O'Brien, Kerry

AU - Seear, Kate

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Recent clinical studies illustrate that psychedelics such as LSD and psilocybin may represent much-needed new treatment options for mood disorders and alcohol and other drug use disorders. More clinical studies are required to confirm the safety and efficacy of psychedelic-assisted therapies, but the cultural stigma that has surrounded psychedelics since the 1960s has hindered research. This problem is amplified in Australia. There has been a complete absence of research into psychedelic therapies, and Australian-based research advocates claim to have encountered a number of barriers. In this commentary, we provide a brief account of the historical stigma associated with psychedelics, and an overview of the contemporary context of research into psychedelic-assisted therapies, including the purported barriers to research in Australia. In light of the complex history of psychedelics, we identify a number of pressing questions relating to the social and legal context that need to be addressed so that clinical studies can proceed. Research is needed to address such questions so that the nature and extent of purported barriers to clinical studies with psychedelics can be properly elucidated, and strategies developed – with practitioners, patients, families and other stakeholders – to responsibly address these barriers. This is important because it will enable Australian researchers to contribute robust evidence about the possible efficacy and safety of psychedelic therapies, and to facilitate local expertise needed to implement psychedelic-assisted therapies, should they prove efficacious.

AB - Recent clinical studies illustrate that psychedelics such as LSD and psilocybin may represent much-needed new treatment options for mood disorders and alcohol and other drug use disorders. More clinical studies are required to confirm the safety and efficacy of psychedelic-assisted therapies, but the cultural stigma that has surrounded psychedelics since the 1960s has hindered research. This problem is amplified in Australia. There has been a complete absence of research into psychedelic therapies, and Australian-based research advocates claim to have encountered a number of barriers. In this commentary, we provide a brief account of the historical stigma associated with psychedelics, and an overview of the contemporary context of research into psychedelic-assisted therapies, including the purported barriers to research in Australia. In light of the complex history of psychedelics, we identify a number of pressing questions relating to the social and legal context that need to be addressed so that clinical studies can proceed. Research is needed to address such questions so that the nature and extent of purported barriers to clinical studies with psychedelics can be properly elucidated, and strategies developed – with practitioners, patients, families and other stakeholders – to responsibly address these barriers. This is important because it will enable Australian researchers to contribute robust evidence about the possible efficacy and safety of psychedelic therapies, and to facilitate local expertise needed to implement psychedelic-assisted therapies, should they prove efficacious.

KW - Addiction

KW - LSD

KW - Mood disorders

KW - Psilocybin

KW - Socio-political

KW - Stigma

UR - http://www.scopus.com/inward/record.url?scp=85066129342&partnerID=8YFLogxK

U2 - 10.1016/j.drugpo.2019.05.019

DO - 10.1016/j.drugpo.2019.05.019

M3 - Comment / Debate

VL - 70

SP - 94

EP - 98

JO - International Journal of Drug Policy

JF - International Journal of Drug Policy

SN - 0955-3959

ER -